Is DOAC A Viable Option After Bioprosthetic Valve Surgery Even in Sinus Rhythm?

(MedPage Today) -- CHICAGO -- Edoxaban (Savaysa) appeared at least on par with warfarin for 12-week thromboembolic prophylaxis after bioprosthetic valve surgical implant in a Japanese trial with a population largely in sinus rhythm, but small...